NASDAQ:HBIO Harvard Bioscience (HBIO) Stock Price, News & Analysis $5.80 +0.03 (+0.43%) As of 10:10 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Harvard Bioscience Stock (NASDAQ:HBIO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Harvard Bioscience alerts:Sign Up Key Stats Today's Range$5.71▼$5.8750-Day Range$4.31▼$7.2452-Week Range$3.10▼$9.50Volume1,752 shsAverage Volume48,841 shsMarket Capitalization$26.18 millionP/E RatioN/ADividend YieldN/APrice Target$6.00Consensus RatingHold Company Overview Harvard Bioscience, Inc. develops, manufactures and distributes life science research instruments and consumables used by academic, biopharmaceutical and government laboratories worldwide. The company’s product portfolio spans cellular physiology, microfluidics, electrophysiology and lab automation, providing tools that enable researchers to study everything from cell behavior and organ function to drug delivery and tissue mechanics. Through its operating units—most notably Harvard Apparatus, BTX, Radnoti and Warner Instruments—Harvard Bioscience offers a diverse range of scientific equipment including precision pumps, stereotaxic instruments, electroporation and gene delivery systems, perfusion systems and microinjection tools. The company serves its customers via direct sales and an extensive distributor network, with significant operations in North America, Europe and the Asia‐Pacific region. Founded in 1901 and headquartered in Holliston, Massachusetts, Harvard Bioscience has grown through organic innovation and strategic acquisitions to support the evolving needs of life science research. The company maintains manufacturing and R&D facilities in the United States and Europe and is managed by an experienced team of professionals with backgrounds in engineering, sales and scientific product development.AI Generated. May Contain Errors. Read More Harvard Bioscience Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks46th Percentile Overall ScoreHBIO MarketRank™: Harvard Bioscience scored higher than 46% of companies evaluated by MarketBeat, and ranked 448th out of 628 stocks in the computer and technology sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.7 / 5Analyst RatingHold Consensus RatingHarvard Bioscience has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 1 sell rating.Upside/DownsideThe consensus price target for Harvard Bioscience is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageHarvard Bioscience has only been the subject of 2 research reports in the past 90 days.Read more about Harvard Bioscience's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Harvard Bioscience is -2.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Harvard Bioscience is -2.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioHarvard Bioscience has a P/B Ratio of 2.59. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Harvard Bioscience's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.36% of the float of Harvard Bioscience has been sold short.Short Interest Ratio / Days to CoverHarvard Bioscience has a short interest ratio ("days to cover") of 3.35, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Harvard Bioscience has recently decreased by 29.17%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldHarvard Bioscience does not currently pay a dividend.Dividend GrowthHarvard Bioscience does not have a long track record of dividend growth. News and Social Media1.3 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 2 news articles for Harvard Bioscience this week, compared to 6 articles on an average week.Search Interest3 people have searched for HBIO on MarketBeat in the last 30 days. MarketBeat Follows1 people have added Harvard Bioscience to their MarketBeat watchlist in the last 30 days. Company Ownership5.0 / 5Insider TradingAcquiring Shares Cluster Insider Buying3 insiders have purchased shares of Harvard Bioscience in the last three months. Multiple insiders buying is a strong bullish signal.Net Insider BuyingOver the last three months, insiders have purchased a net $177,354.00 in company stock, which represents 0.6815% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Harvard Bioscience insiders have bought more of their company's stock than they have sold. Specifically, they have bought $177,354.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders20.30% of the stock of Harvard Bioscience is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions80.87% of the stock of Harvard Bioscience is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Harvard Bioscience's insider trading history. Receive HBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Harvard Bioscience and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. HBIO Stock News HeadlinesHarvard Bioscience Maps Turnaround With Project Viking, Recurring Revenue PushMay 25 at 5:03 AM | americanbankingnews.comHarvard Bioscience Balances Margin Gains With Soft SalesMay 19, 2026 | tipranks.comJune 12: $100 Turns Into $100,000?The SpaceX IPO is scheduled for June 12, and former tech executive Jeff Brown - who identified Bitcoin, Tesla, and Nvidia before major runs - says the window to get in early is closing fast. Brown is showing investors how to claim a stake in Elon Musk's company before it hits the public markets. Once the IPO happens, this pre-public opportunity disappears.May 28 at 1:00 AM | Brownstone Research (Ad)HBIO Q1 2026 Earnings TranscriptMay 14, 2026 | finance.yahoo.comHarvard Bioscience: Q1 Earnings SnapshotMay 14, 2026 | finance.yahoo.comHarvard Bioscience, Inc.: Harvard Bioscience Announces First Quarter 2026 Financial ResultsMay 12, 2026 | finanznachrichten.deHarvard Bioscience, Inc. (HBIO) Q1 2026 Earnings Call TranscriptMay 12, 2026 | seekingalpha.comHarvard Bioscience Unveils Strategic Transformation Toward Translational ToolsMay 12, 2026 | tipranks.comSee More Headlines HBIO Stock Analysis - Frequently Asked Questions How have HBIO shares performed this year? Harvard Bioscience's stock was trading at $6.6880 on January 1st, 2026. Since then, HBIO shares have decreased by 13.7% and is now trading at $5.77. How were Harvard Bioscience's earnings last quarter? Harvard Bioscience, Inc. (NASDAQ:HBIO) released its quarterly earnings data on Tuesday, May, 12th. The medical instruments supplier reported ($0.33) earnings per share for the quarter, beating the consensus estimate of ($0.62) by $0.29. The medical instruments supplier earned $20.76 million during the quarter, compared to the consensus estimate of $21.20 million. Harvard Bioscience had a negative trailing twelve-month return on equity of 25.78% and a negative net margin of 11.44%. Read the conference call transcript. When did Harvard Bioscience's stock split? Shares of Harvard Bioscience reverse split on the morning of Monday, March 16th 2026.A 1-10 reverse split was announced. The number of shares owned by shareholders was adjusted after the market closes on Sunday, March 15th 2026. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. Does Harvard Bioscience have any subsidiaries? Harvard Bioscience subsidiaries include these companies: Data Sciences International. How do I buy shares of Harvard Bioscience? Shares of HBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Harvard Bioscience own? Based on aggregate information from My MarketBeat watchlists, some other companies that Harvard Bioscience investors own include YETI (YETI), Advanced Micro Devices (AMD), Meta Platforms (META), NVIDIA (NVDA), Alphabet (GOOG), Stag Industrial (STAG) and Tesla (TSLA). Company Calendar Last Earnings5/12/2026Today5/28/2026Next Earnings (Estimated)8/10/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1w+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 For the last 8 days, HBIO's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorComputer and Technology Industry INSTRU - SCIENTFC Sub-IndustryLife Sciences Tools & Services Current SymbolNASDAQ:HBIO CIK1123494 Webwww.harvardbioscience.com Phone(508) 893-8999Fax508-429-5732Employees490Year Founded1901Price Target and Rating Average Price Target for Harvard Bioscience$6.00 High Price Target$6.00 Low Price Target$6.00 Potential Upside/Downside+4.0%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($2.17) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$56.70 million Net Margins-11.44% Pretax Margin-11.57% Return on Equity-25.78% Return on Assets-4.37% Debt Debt-to-Equity Ratio3.60 Current Ratio1.99 Quick Ratio1.06 Sales & Book Value Annual Sales$86.55 million Price / Sales0.30 Cash Flow$11.78 per share Price / Cash Flow0.49 Book Value$2.23 per share Price / Book2.59Miscellaneous Outstanding Shares4,510,000Free Float3,594,000Market Cap$26.02 million OptionableOptionable Beta1.57 Social Links Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (NASDAQ:HBIO) was last updated on 5/28/2026 by MarketBeat.com Staff. From Our PartnersWall Street’s $3.3B critical mineral darling just got spanked by a $300M junior …NevGold Corp. (OTCQX: NAUFF) just released drill results showing up to 53.71% antimony - potentially one of th...i2i Marketing Group, LLC | SponsoredBNZI Breakout Watch: AI Growth Meets Turnaround Setup!Banzai International (NASDAQ: BNZI) reported full-year 2025 revenue of $12.2 million, up 169% year-over-year, ...Huge Alerts | SponsoredHow to claim a stake in SpaceX before the June 12 IPOSpaceX is expected to go public on June 12 - and for the first time, everyday investors may have a way in befo...Brownstone Research | SponsoredThe "hidden" half of the SpaceX IPOMost investors are focused on the SpaceX IPO - but the bigger opportunity may lie elsewhere. On Feb. 2, Elon M...Weiss Ratings | SponsoredNevada gold explorer near Kinross district draws attentionGold has surged past $5,300 per ounce, with Goldman Sachs and JPMorgan forecasting $6,000+ by end of 2026. Cen...Wall Street Logic | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredThey're not telling you how bad this could getValuations are stretched to levels seen only a handful of times in the last hundred years — yet most retiremen...Parkview Capital Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Harvard Bioscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Harvard Bioscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
